Skip to main content
Top

12-09-2017 | Hypoglycemia | Article

Treatment of mild-to-moderate hypoglycemia in patients with type 1 diabetes treated with insulin pump therapy: are current recommendations effective?

Journal: Acta Diabetologica

Authors: Véronique Gingras, Katherine Desjardins, Mohamed Raef Smaoui, Valérie Savard, Virginie Messier, Ahmad Haidar, Laurent Legault, Rémi Rabasa-Lhoret

Publisher: Springer Milan

Abstract

Aims

Mild-to-moderate hypoglycemia (blood glucose < 4.0 mmol/L) is recommended to be treated with 15 g of carbohydrates and to repeat the treatment if hypoglycemia persists after 15 min. This recommendation was established before intensive insulin therapy and based on studies using insulin with different pharmacokinetic profiles from actual insulin analogs showing that 15 g of glucose increases blood glucose by ~ 1.5 mmol/L in 15 min. We aimed to explore the effect of current recommended treatment of mild-to-moderate hypoglycemia in type 1 diabetes (T1D) participants and factors associated with treatment effectiveness.

Methods

This is a secondary analysis from three observational inpatient studies with a standardized and supervised treatment (16 g carbohydrates) of hypoglycemia (< 3.3 mmol/L with symptoms or < 3.0 mmol/L without symptom) in participants (47 adults–10 adolescents) with T1D using continuous subcutaneous insulin infusion (“insulin pumps”; CSII)).

Results

Twenty-seven participants presented a total of 48 hypoglycemia episodes treated by a single intake of 16 g of carbohydrates. Time required for normoglycemia recovery was 19.5 ± 12.0 min. The rise in plasma glucose following treatment was 0.85 ± 0.66 mmol/L in 15 min. Eighteen episodes (38%) were resolved (> 4.0 mmol/L) 15-min post-treatment. Glycemia at the time of treatment (< 3.2 mmol/L; p < 0.001) and a higher proportion of total daily insulin from basal doses (p = 0.03) were associated with a slower post-treatment plasma glucose rise.

Conclusions

These results raise the possibility that sixteen grams of carbohydrates could be insufficient to treat a large proportion of hypoglycemia episodes in T1D patients treated with CSII. Factors affecting treatment effectiveness need to be investigated.
Literature
1.
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977–986CrossRef
2.
Clayton D, Woo V, Yale JF, Canadian Diabetes Association Clinical Practice Guidelines Expert C (2013) Hypoglycemia. Can J Diabetes 37(Suppl 1):S69–S71CrossRefPubMed
3.
Brazeau AS, Rabasa-Lhoret R, Strychar I, Mircescu H (2008) Barriers to physical activity among patients with type 1 diabetes. Diabetes Care 31(11):2108–2109CrossRefPubMedPubMedCentral
4.
American Diabetes Association (2016) Standards of medical care in diabetes. Diabetes Care 39(Suppl. 1):S72–S80
5.
Banck-Petersen P, Larsen T, Pedersen-Bjergaard U, Due-Andersen R, Høi-Hansen T, Thorsteinsson B (2007) Adherence to guidelines for self-treatment of mild hypoglycaemia in type 1 diabetes. Eur Diabetes Nurs 4(1):18–22CrossRef
6.
Sally A, Vindedziz BM, Sherriff JL, Dhaliwal SS, Stanton KG (2012) Food selection for treatment of hypoglycaemia in insulin-treated diabetes: what happens in real life? Pract Diabetes 29(7):271–274CrossRef
7.
Savard V, Gingras V, Leroux C, Bertrand A, Desjardins K, Mircescu H, Rabasa-Lhoret R (2016) Treatment of hypoglycemia in adult patients with type 1 diabetes: an observational study. Can J Diabetes 40(4):318–323CrossRefPubMed
8.
Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R (2015) Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol 3(1):17–26CrossRefPubMed
9.
Haidar A, Legault L, Dallaire M, Alkhateeb A, Coriati A, Messier V, Cheng P, Millette M, Boulet B, Rabasa-Lhoret R (2013) Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ 185(4):297–305CrossRefPubMedPubMedCentral
10.
Gingras V, Rabasa-Lhoret R, Messier V, Ladouceur M, Legault L, Haidar A (2016) Efficacy of dual-hormone artificial pancreas to alleviate the carbohydrate-counting burden of type 1 diabetes: a randomized crossover trial. Diabetes Metab 42(1):47–54CrossRefPubMed
11.
Slama G, Traynard PY, Desplanque N, Pudar H, Dhunputh I, Letanoux M, Bornet FR, Tchobroutsky G (1990) The search for an optimized treatment of hypoglycemia. Carbohydrates in tablets, solution, or gel for the correction of insulin reactions. Arch Intern Med 150(3):589–593CrossRefPubMed
12.
Brodows RG, Williams C, Amatruda JM (1984) Treatment of insulin reactions in diabetics. JAMA 252(24):3378–3381CrossRefPubMed
13.
The Diabetes Control and Complications (DCCT) Research Group (1995) Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47(6):1703–1720
14.
Diabetes Control and Complications Trial Research Group (2001) Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 24(10):1711–1721CrossRef
15.
Wong JC, Foster NC, Maahs DM, Raghinaru D, Bergenstal RM, Ahmann AJ, Peters AL, Bode BW, Aleppo G, Hirsch IB et al (2014) Real-time continuous glucose monitoring among participants in the T1D exchange clinic registry. Diabetes Care 37(10):2702–2709CrossRefPubMedPubMedCentral
16.
Benkhadra K, Alahdab F, Tamhane S, Wang Z, Prokop LJ, Hirsch IB, Raccah D, Riveline JP, Kordonouri O, Murad MH (2017) Real-time continuous glucose monitoring in type 1 diabetes: a systematic review and individual patient data meta-analysis. Clin Endocrinol (Oxf) 86(3):354–360CrossRef
17.
King AB, Kuroda A, Matsuhisa M, Hobbs T (2016) A review of insulin-dosing formulas for continuous subcutaneous insulin infusion (CSII) for adults with type 1 diabetes. Curr Diab Rep 16(9):83CrossRefPubMedPubMedCentral
18.
McTavish L, Krebs JD, Weatherall M, Wiltshire E (2015) Weight-based hypoglycaemia treatment protocol for adults with Type 1 diabetes: a randomized crossover clinical trial. Diabet Med 32(9):1143–1148CrossRefPubMed
19.
Vindedzis S, Marsh B, Sherriff J, Dhaliwal S, Stanton K (2012) Dietary treatment of hypoglycaemia: should the Australian recommendation be increased? Intern Med J 42(7):830–833CrossRefPubMed
20.
Cryer PE, Davis SN, Shamoon H (2003) Hypoglycemia in diabetes. Diabetes Care 26(6):1902–1912CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »